MicroRNAs miR-19, miR-340, miR-374 and miR-542 regulate MID1 protein expression

Kristoffer Unterbruner\(^1\)*, Frank Matthes\(^1\)*, Judith Schilling\(^1\), Rohit Nalavade\(^3\), Stephanie Weber\(^1\), Jennifer Winter\(^2,3\), Sybille Krauß\(^1\)*

1 Regulatory RNA-protein interactions in neurodegenerative diseases, German Center for Neurodegenerative Diseases (DZNE), Bonn, North Rhine-Westphalia, Germany, 2 Institute of Human Genetics, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Rhineland-Palatinate, Germany, 3 Focus Program of Translational Neurosciences, Johannes Gutenberg University Mainz, Mainz, Rhineland-Palatinate, Germany

* These authors contributed equally to this work.
* sybille.krauss@dzne.de

Abstract

The MID1 ubiquitin ligase activates mTOR signaling and regulates mRNA translation. Misregulation of MID1 expression is associated with various diseases including midline malformation syndromes, cancer and neurodegenerative diseases. While this indicates that MID1 expression must be tightly regulated to prevent disease states specific mechanisms involved have not been identified. We examined miRNAs to determine mechanisms that regulate MID1 expression. MicroRNAs (miRNA) are small non-coding RNAs that recognize specific sequences in their target mRNAs. Upon binding, miRNAs typically downregulate expression of these targets. Here, we identified four miRNAs, miR-19, miR-340, miR-374 and miR-542 that bind to the 3’-UTR of the MID1 mRNA. These miRNAs not only regulate MID1 expression but also mTOR signaling and translation of disease associated mRNAs and could therefore serve as potential drugs for future therapy development.

Introduction

The RING finger protein MID1 is involved in fundamental cellular processes including somatic cell growth and proliferation as well as neuron function (reviewed in [1]). Acting as E3 ubiquitin ligase MID1 marks the mTOR antagonist protein phosphatase 2A (PP2A) for degradation by the proteasome and thereby enhances mTOR activity [2]. Furthermore, MID1 assembles a ribonucleoprotein complex and regulates translation [3–6].

Germline mutations in \textit{MID1} cause Opitz BBB/G syndrome (OS), a rare monogenic disorder involving malformations of the ventral midline including hypertelorism and hypospadias among others. Besides its role in OS MID1 function has been associated with the development and progression of various other diseases including cancer and neurodegenerative diseases. MID1 is overexpressed in certain cancer types and promotes cancer growth [7, 8]. In the brain, MID1 binds to and induces translation of pathologically expanded CAG repeat mRNAs, which are the cause for neurodegenerative diseases such as Huntington’s disease and...
spinocerebellar ataxias [5, 6]. Reducing the expression of MID1 is a promising new option to treat these diseases.

MiRNAs are endogenously expressed short (~20 nucleotide long) non-coding RNAs that base-pair their mRNA targets with imperfect complementarity (reviewed in [9]). The so-called “seed region” comprising nucleotides 2–8 of the miRNA, however, shows perfect complementarity and is important for target recognition. MiRNA binding sites are often located in the 3’-untranslated region (3’-UTR) of their target mRNAs [10–12]. Binding of a miRNA to its target mRNA can either cause degradation or inhibit translation.

Mimics of miRNAs that target MID1 could be promising miRNA therapeutics to treat cancer as well as neurodegenerative diseases. Whether MID1 is subject to miRNA targeting was, however, unknown. Here, we identified four miRNAs, miR-19, miR-340, miR-374 and miR-542 that bind the 3’-UTR of MID1 mRNA and inhibit MID1 protein production.

Materials and methods

Human brain tissue was collected and stored as previously described [13]. Tissue was obtained with the families’ full consent and with the approval of the Leiden University Medical Center institutional Ethics Committee.

Prediction of miRNA binding sites

MiRNA binding sites in the MID1 mRNA (Human MID1 ENST00000453318.2) were predicted using TargetScanHuman 6.2 (http://www.targetscan.org).

Constructs

The first 1352 nucleotides of the MID1 3’-UTR containing the predicted binding sites of the above-mentioned miRNAs were cloned into the psiCHECK-2 vector (Promega) downstream of the renilla luciferase gene using the restriction enzymes NotI and XhoI.

MiRNA mimics and inhibitors transfections and luciferase reporter assays

Chemically synthesized double-stranded RNAs mimicking mature endogenous miRNAs were transfected into HEK293T cells (ATCC) or HEK293T cells stably expressing HTT-exon1 with 51 CAG repeats [14] or into SH-SY5Y cells (ATCC). 10⁵ cells per well of a 24-well plate were seeded one day prior transfection. 2.5 μl per well of a 20 μM stock of miRNA mimics (hsa-miR-374a-5p, hsa-miR-542-3p, hsa-miR-216a-5p, hsa-miR-19b-3p, and hsa-miR-340-5p miScript miRNA Mimics, Qiagen) or miRNA inhibitors (hsa-miR-216a-5p, hsa-miR-340-3p, hsa-miR-374a, and hsa-miR-542-3p inhibitors from Qiagen, hsa-miR-19b-3p inhibitor from Sigma Aldrich (HSTUD0344)) were transfected using Oligofectamine (Invitrogen/Thermo Fisher Scientific) according to the manufacturer’s instructions. Twenty-four hours after transfection with mimics or inhibitors cells were transfected with plasmid DNA using Lipofectamine 2000 (Invitrogen/Thermo Fisher Scientific) according to the manufacturer’s instructions. Twenty-four hours later cells were lysed in 1x PLB (Promega) and protein concentration was measured by following the Qubit® Protein Assay kit (Thermo Fisher Scientific). Samples were diluted to a concentration of 1 μg/μl. 10 μl of the diluted lysate was pipetted into a 96-well plate and luciferase assay was performed using the Dual-Luciferase® Reporter Assay System kit (Promega) following the manufacturer’s instructions. Measurement was performed in a FLUOstar Omega plate reader (BMG Labtech).
Western blot

Cells were transfected with miRNA mimics, inhibitors, MID1 siRNAs (pool 5 siRNAs: TTGAGTGAGCGCTATGACAAA, AAGGTGATGAGGCTT CGCAAA, TAGAACGTGATGACATCATCAT, CACCGCAUCCUAGUAUCACTT, CAGGAUUAACUUUUUGGATT) or non-silencing control siRNAs (AATTCTCCGAACGTGTACAGT) and lysed as described above. After addition of 4x SDS PAGE buffer (EDTA 50 mM, Tris 200 mM, glycerol 40%, SDS 8%, β-mercaptoethanol 4%, bromophenol blue 0.008%) samples were boiled for 10 min at 95˚C and proteins were analyzed on 10% SDS gels and blotted onto PVDF membranes (Roche). Blots were blocked in milk and incubated with the following antibodies: anti-actin (Abcam, rabbit), HRP-anti-rabbit (Cell signaling). For production of polyclonal MID1 antibodies MID1-peptides were synthesized (amino acids 84–113) and used for immunisation of rabbits (PINEDA). Eight weeks after immunisation high-titre sera were collected and affinity purified using the peptide coupled to SulfoLink Coupling Resin (Thermo Scientific) following the manufacturer’s instructions. The purified antibodies were validated on western blots of lysates from MID1 knockdown cells, as well as in western blot experiments in which peptide-blocking was performed (S1 Fig). The resulting bands were quantified using Image/J software. Statistical analyses were performed using one-way ANOVA with post hoc Dunnett’s test to accommodate for multiple comparisons or Student’s t-test for two-group comparisons, as appropriate.

Quantitative real-time PCR (qPCR)

Total RNA was isolated using the RNeasy Plus Mini Kit (Qiagen) according to the manufacturer’s instructions. cDNA was synthesized using the TaqMan reverse transcription reagents kit (Applied Biosystems) and qPCR was carried out using the SYBRGreen PCR master mix (Applied Biosystems). Primers used: GAPDH forward: CCACCCATGGCAAATTCC, GAPDH reverse: TGGGATTTCTCATTGACAAAG, MID1 forward: CTGCCAGGTTCCTGACAGAT, MID1 reverse: AATCAGGCTTAGGGCCTTCT.

Reverse transcription PCR (RT-PCR)

To detect miRNAs in HEK293T cells, a miRNA-enriched fraction was purified using the miRNeasy Mini and MinElute Cleanup Kits (Qiagen) according to the manufacturer’s instructions. MiRNAs were subjected to poly(T) adaptor reverse transcription as described (Shi et al., 2012) using E. coli poly(A) polymerase (New England Biolabs) and the TaqMan reverse transcription kit (Applied Biosystems) in a combined reaction. MiRNA sequences were amplified by PCR using miRNA-specific forward primers and the described universal poly(T) adaptor reverse primer. Primers used: hsa-miR-19b-3p-fwd: TGTGCAAATCCATGCAAAA CTGA, hsa-miR-216a-5p-fwd: TAACTCGACGTTGAGCAAATGGA, hsa-miR-340-5p-fwd: GCTTTAAAGCAAT GAGACTGAAT, hsa-miR-374a-5p-fwd: CGTTTTAAACACCCGATAAGTG, hsa-miR-542-3p-fwd: GCTGTGACAGATTGATAAC TGAAA.

Results

MiRNAs hsa-miR-374a-5p, hsa-miR-542-3p, hsa-miR-216a-5p, hsa-miR-19b-3p, and hsa-miR-340-5p target the MID1 3’-UTR at specific sites

The software Targetscan predicted several miRNAs to target the MID1 3’-UTR (Fig 1A). Because the MID1 3’-UTR is subject to several alternative polyadenylation events we only picked miRNAs that were predicted to target sequences in the 5’-part of the MID1 3’-UTR for further analysis. Furthermore, we restricted our analysis to miRNAs whose predicted binding

PLOS ONE | https://doi.org/10.1371/journal.pone.0190437 January 2, 2018 3 / 15
sites in the MID1 3'-UTR were highly conserved in vertebrates (has-miR-19b-3p, has-miR216a-5p) or mammals (hsa-miR-374a-5p, hsa-miR-542-3p, hsa-miR-340-5p).

To test for binding of the miRNAs to the MID1 3'-UTR a luciferase reporter vector containing the first 1352 nucleotides of the MID1 3'-UTR cloned downstream of the renilla luciferase together with a pool of miRNA mimics or miRNA inhibitors was transfected into HEK293T cells and luciferase activity was measured. The pools were comprised of mimics or inhibitors of all five miRNAs. Firefly luciferase expressed from the same plasmid as renilla luciferase was used for normalization. Endogenous expression of these five miRNAs in HEK293T cells has been reported previously (miRmine Human miRNA Expression Database, [15]) and we validated this finding by reverse transcription PCR (S2 Fig).

Transfecting the pool of miRNA mimics and inhibitors significantly decreased or increased, respectively, the activity of the MID1 luciferase reporter (Fig 2A), suggesting that miRNAs hsa-miR-374a-5p, hsa-miR-542-3p, hsa-miR-216a-5p, hsa-miR-19b-3p, and hsa-miR-340-5p indeed target the MID1 3'-UTR. To test each miRNA individually for its capacity to target the MID1 3'-UTR we mutated the respective miRNA binding sites in the MID1 luciferase reporter constructs (Fig 1B). These mutant constructs were co-transfected with the corresponding miRNA mimics and compared to transfections of the non-mutated constructs. A significant increase in luciferase activity could be observed upon transfection of all mutant constructs except for the construct containing the mutated miR-216 binding site (Fig 2B). These data show that miRNAs hsa-miR-374a-5p, hsa-miR-542-3p, hsa-miR-19b-3p, and hsa-miR-340-5p but not miR-216a-5p target the MID1 3'-UTR at the predicted sites.
MiRNAs hsa-miR-374a-5p, hsa-miR-542-3p, hsa-miR-19b-3p, and hsa-miR-340-5p target endogenous MID1

To test if miRNAs hsa-miR-374a-5p, hsa-miR-542-3p, hsa-miR-19b-3p, and hsa-miR-340-5p target endogenous MID1, we transfected a pool of the corresponding miRNA mimics into HEK293T cells and analyzed the expression level of MID1 by qPCR and on western blots. In line with the above-mentioned luciferase reporter experiments, transfection of the miRNA mimics pool led to a significant reduction of MID1 expression at both RNA (Fig 3A) and protein level (Fig 3B). Consistently, transfection of miRNA inhibitors had the opposite effect and led to a significant increase in endogenous MID1 protein level (Fig 3C, S3 Fig, S4 Fig). Together these data indicate that miRNAs hsa-miR-374a-5p, hsa-miR-542-3p, hsa-miR-19b-3p, and hsa-miR-340-5p regulate MID1 expression.

Targeting of MID1 by miRNAs hsa-miR-374a-5p, hsa-miR-542-3p, hsa-miR-19b-3p, and hsa-miR-340-5p reduces translation of MID1-target mRNAs

One previously described cellular function of the MID1 protein is the regulation of translation of its target mRNAs. MID1 induces translation of pathologically expanded CAG repeat mRNAs, such as huntingtin (HTT) mRNA [5, 6]. A miRNA-mediated reduction in MID1 should decrease protein levels of mutant HTT accordingly. To test this hypothesis, we transfected a previously described cell culture model for Huntington’s disease [14] with a pool of miRNA mimics (hsa-miR-374a-5p, hsa-miR-542-3p, hsa-miR-19b-3p, and hsa-miR-340-5p).
These cells, a derivative of HEK293T stably expressing HTT-exon 1 with 51 CAG-repeats, were transfected either with the pool of MID1-targeting miRNA mimics or non-silencing control siRNA oligonucleotides. Cells were analyzed for HTT-exon 1 protein expression by western blot analysis. As expected, depletion of MID1 by miRNA mimics resulted in a significant reduction of HTT protein (Fig 4A, S5 Fig, S6 Fig).

MID1 inhibits PP2A, which in turn affects the phosphorylation of the translational regulator S6K and its target protein, the ribosomal subunit S6 [2, 5]. A decrease in MID1 expression leads to an upregulation of PP2A and dephosphorylation of S6K and S6. To test whether MID1-regulating miRNAs have an effect on S6 phosphorylation we measured S6 phosphorylation by western blot analysis upon transfection of the miRNA mimics pool containing mimics of hsa-miR-374a-5p, hsa-miR-542-3p, hsa-miR-19b-3p, and hsa-miR-340-5p. As expected
expressing the miRNA mimic pool caused a strong reduction in S6 phosphorylation (Fig 4B, S7 Fig, S8 Fig).

The androgen receptor (AR) mRNA is another important MID1 target [7]. To test if depletion of MID1 by miRNAs hsa-miR-374a-5p, hsa-miR-542-3p, hsa-miR-19b-3p, and hsa-miR-340-5p results in decreased AR protein levels, we transfected SH-SY5Y cells with the same pool of miRNA mimics as before. As positive control MID1-specific siRNAs and as a negative control non-silencing siRNAs were used. Cells were analyzed for MID1 and AR protein expression by western blot analysis. As expected, depletion of MID1 by miRNA mimics resulted in a significant reduction of AR protein (Fig 5, S9 Fig, S10 Fig, S11 Fig, S12 Fig). Taken together, these data show that depletion of MID1 by miRNAs hsa-miR-374a-5p, hsa-miR-542-3p, hsa-miR-19b-3p, and hsa-miR-340-5p leads to a reduction of several known MID1-targets: mutant HTT, S6 and AR.

Discussion

In the embryo, MID1 is a dosage sensitive gene and is important for the development of ventral midline structures. In the adult, however, abnormal MID1 function has been associated with neurodegenerative diseases as well as cancer. Reducing MID1 expression in patients suffering from these diseases may be a promising therapeutic option. MiRNA-based therapeutics such as miRNA mimics could potentially be used to achieve such a downregulation of MID1 in disease state. Only one miRNA, miR-135b, has been shown previously to bind the MID1 3’-UTR and regulate MID1 expression in breast cancer cells [16]. Here we identified four additional miRNAs, hsa-miR-19b-3p, hsa-miR-340-5p, hsa-miR-374a-5p and hsa-miR-542-3p, that target the MID1 3’-UTR and regulate MID1 expression (Fig 6).

MID1 enhances the translation of mutant CAG repeat mRNAs and is therefore contributing to the neuropathology of polyglutamine diseases such as Huntington’s disease [5, 6]. Additionally, MID1 regulates processes that are linked to carcinogenesis and an abnormal activity of MID1 has been shown in different cancer cell types [7, 8]. Furthermore, MID1 expression is increased in certain types of cancer for example in prostate cancer cells [7]. Mechanistically, a carcinogenic action of MID1 can be explained by its interaction with proteins that play a role in cell cycle regulation. For example, MID1 regulates expression of CyclinD1 via the transcription factor GLI3 [8, 17]. Furthermore, MID1 regulates activity of PP2A [2], a well established regulator of the cell cycle (reviewed in [18]). Whereas the four MID1-targeting miRNAs that we have identified have not been linked to Huntington’s disease so far, all of them have previously been linked to carcinogenesis [19–25]. Interestingly, expression of hsa-miR-19b-3p is

![Fig 5. Targeting of endogenous MID1 by miRNA s hsa-miR-374a-5p, hsa-miR-542-3p, hsa-miR-19b-3p, and hsa-miR-340-5p leads to a reduction of AR protein.](https://doi.org/10.1371/journal.pone.0190437.g005)
MiR-19, miR-340, miR-374 and miR-542 regulate MID1

Fig 6. Model showing the role of MID1 in diverse diseases. We identified miRNAs hsa-miR-374a-5p, hsa-miR-542-3p, hsa-miR-19b-3p, and hsa-miR-340-5p as regulators of MID1. By controlling the expression levels of MID1 these miRNAs may affect several MID1-dependent processes. Functionally, MID1 acts as E3 ubiquitin ligase. Known targets of MID1’s ubiquitin ligase activity include PP2A and Fu. By catalyzing the ubiquitination PP2A MID1 induces the proteasomal degradation of PP2A, thereby reducing PP2A activity towards its target proteins. These include proteins involved in transcription regulation of inflammatory genes via NF-κB signaling, which are especially involved in chronic inflammatory diseases such as asthma or eosinophilic oesophagitis, as well as the Tau protein, that is important in Alzheimer’s disease. Besides inhibiting PP2A MID1 stimulates the activity of mTOR. PP2A and mTOR regulate phosphorylation and thereby activity of the translational regulator S6K. Via PP2A and mTOR, MID1 controls translation of its target mRNAs. These include APP and BACE1, which play an important role in Alzheimer’s disease, mutant HTT, which causes Huntington’s disease, as well as the androgen receptor (AR), which is involved in prostate cancer. The second known target of MID1’s ubiquitin ligase activity is the kinase Fu. Upon MID1-dependent ubiquitination, this protein gets cleaved, which produces an active truncated protein that regulates the transcription factor GLI3.

https://doi.org/10.1371/journal.pone.0190437.g006

down-regulated in gastric cancer [19] and hsa-miR-542-3p is decreased in several cancer types including oral squamous cell carcinoma [26], serous ovarian tumor [22], esophageal cancer [24] and colorectal cancer [25] and acts as a tumor suppressor miRNA. Future studies should investigate whether a downregulation of these miRNAs is functionally connected to an upregulation of MID1 in these cancers.

MicroRNAs have oftentimes more than one target and can regulate the expression of several genes. In addition to MID1, miRNAs hsa-miR-19b-3p, hsa-miR-340-5p, hsa-miR-374a-5p and hsa-miR-542-3p have other target mRNAs (Table 1). Several of these known target
mRNAs are associated with carcinogenesis. For example, hsa-miR-19b-3p regulates PTEN, a tumor suppressor that is mutated in a large number of cancers [27], and ESR1, mutations in which are associated with breast cancer [28].

Hsa-miR-340-5p regulates expression of oncogenic target mRNAs. For example, MET is a proto-oncogene [45], KRAS is a proto-oncogene [46], and overexpression of RHOA leads to tumor formation [47]. Hsa-miR-542-3p acts as tumor suppressor by targeting survivin (BIRC5) [29, 30], the oncogene astrocyte-elevated gene-1 (MTDH) [38], or angiopoietin-2 (ANGPT2) that plays a role in tumor angiogenesis [41]. Hsa-miR-374a-5p interferes with carcinogenesis by regulating Srcin1, which contributes to the growth and metastasis of colorectal cancer [31], or by regulating WIF1 that acts as tumor suppressor [32]. Interestingly, we identified MID1 as the first common target of these four miRNAs.

Another interesting observation is that a significantly decreased expression of miR-19b-3p has been reported to coincide with increased protein expression of BACE1 in Alzheimer’s disease, although miR-19b-3p does not directly target BACE1 [72]. We show here that miR-19b-3p targets MID1, a protein that we have previously shown to induce protein expression of two mRNAs that are crucial for the development of amyloid plaques in Alzheimer’s disease, namely BACE1 [4] and APP [73]. Furthermore, we have observed increased expression of MID1 in Alzheimer’s disease brains [74]. Our data showing that miR-19b-3p targets MID1 provide one possible explanation for increased expression of MID1 in Alzheimer’s disease tissue, that may be caused by reduced levels of miR-19b-3p [72, 75]. Future studies should address if miRNA based therapeutics such as miRNA mimics of the four MID1-targeting miRNAs hsa-miR-19b-3p, hsa-miR-340-5p, hsa-miR-374a-5p and hsa-miR-542-3p could be used to downregulate MID1 in Alzheimer’s disease models and thereby counteract formation of amyloid plaques.

### Table 1. Targets of miRNAs hsa-miR-19b-3p, hsa-miR-340-5p, hsa-miR-374a-5p and hsa-miR-542-3p.

| miRNA: | hsa-miR-19b-3p | hsa-miR-340-5p | hsa-miR-374a-5p | hsa-miR-542-3p |
|--------|----------------|----------------|-----------------|----------------|
| target mRNA | ATXN1 [33] | ABCB5 [34] | CEBPB [35] | BIRC5 [36] |
| | BCL2L11 [37] | HNRNPA2B1 [38] | MID1 | ILK [39] |
| | CUL5 [40] | KRAS [41] | PTEN [42] | MTDH [43] |
| | CYP19A1 [44] | LPAATβ [45] | SRCIN1 [46] | BMP7 [47] |
| | ESR1 [48] | MECP2 [41] | WIF1 [42] | RPS23 [23] |
| | GCM1 [44] | MET [49] | WNT5A [50] | ANGPT2 [51] |
| | MID1 | MID1 | | FZD7 [52] |
| | MTD1 [53] | PTBP1 [38] | | PIM1 [54] |
| | MYCN [55] | RHOA [56] | | cortactin [57] |
| | PPP2R5E [37] | ROCK1 [58] | | AKT1 [59] |
| | PRKAA1 [37] | SOX2 [60] | | integrin-linked kinase [59] |
| | PTEN [61] | STAT3 [62] | | PI3K [59] |
| | Ring finger protein 11 [63] | | | sphingosine-1-phosphate receptor 1 [64] |
| | SMAD4 [65] | | | UBE3C [66] |
| | SOCS1 [67] | | | MID1 |
| | TGF-βRII [68] | | | |
| | TLR2 [69] | | | |
| | TNFAIP3 [70] | | | |
| | TP53 [71] | | | |

https://doi.org/10.1371/journal.pone.0190437.t001
Supporting information

S1 Fig. Validation of the polyclonal MID1 antibody. (a) HEK293T cells were transfected with non-targeting ("control") or MID1-specific siRNAs, lysed, and subjected to western blotting using the MID1 antibody for detection, either in absence (left) or presence (right) of the immunizing peptide (1 μg/ml). The antibody detects a specific band at ~75 kDa, that is reduced in MID1 knockout samples. Blocking with the immunizing peptide results in total loss of the specific signal. (b) Human temporal cortex lysate was subjected to western blotting using the MID1 antibody in absence or presence of the immunizing peptide. The antibody detects two specific bands.

(TIF)

S2 Fig. MicroRNA expression in HEK293T cells. From HEK293T total RNA a miRNA-enriched fraction was prepared. RNAs were extended by a poly(A) tailing reaction followed by reverse transcription using a poly(T) adaptor primer. MiRNA sequences were amplified by PCR using miRNA-specific forward primers and a universal poly(T) adaptor reverse primer. Samples in which reverse transcriptase was omitted (No RT) were used as controls.

(TIF)

S3 Fig. Full blot of the western blot shown in Fig 3C (detection anti-MID1 antibody).

(TIF)

S4 Fig. Full blot of the western blot shown in Fig 3C (detection anti-actin antibody).

(TIF)

S5 Fig. Full blot of the western blot shown in Fig 4A (detection anti-HTT antibody).

(TIF)

S6 Fig. Full blot of the western blot shown in Fig 4A (detection anti-actin antibody).

(TIF)

S7 Fig. Full blot of the western blot shown in Fig 4B (detection anti-pS6 antibody).

(TIF)

S8 Fig. Full blot of the western blot shown in Fig 4B (detection anti-S6 antibody).

(TIF)

S9 Fig. Full blot of the western blot shown in Fig 5A (detection anti-MID1 antibody).

(TIF)

S10 Fig. Full blot of the western blot shown in Fig 5A (detection anti-actin antibody).

(TIF)

S11 Fig. Full blot of the western blot shown in Fig 5B (detection anti-AR antibody).

(TIF)

S12 Fig. Full blot of the western blot shown in Fig 5B (detection anti-actin antibody).

(TIF)

S1 Appendix. Primary data of graphs shown in Figs 2, 3, 4 and 5.

(XLSX)

Acknowledgments

We thank Willeke van Roon-Mom (Leiden University Medical Center) for providing human brain lysates for validation of the MID1-anitbody on western blots.
Author Contributions

Conceptualization: Jennifer Winter, Sybille Krauß.

Data curation: Kristoffer Unterbruner, Frank Matthes, Judith Schilling, Rohit Nalavade, Sybille Krauß.

Formal analysis: Kristoffer Unterbruner, Frank Matthes, Judith Schilling, Rohit Nalavade, Sybille Krauß.

Investigation: Kristoffer Unterbruner, Frank Matthes, Judith Schilling, Rohit Nalavade, Stephanie Weber, Sybille Krauß.

Supervision: Sybille Krauß.

Writing – original draft: Jennifer Winter, Sybille Krauß.

Writing – review & editing: Jennifer Winter, Sybille Krauß.

References

1. Winter J, Basilicata MF, Stemmler MP, Krauss S. The MID1 protein is a central player during development and in disease. Front Biosci (Landmark Ed). 2016; 21:664–82. PMID: 26709798.

2. Trockenbacher A, Suckow V, Foerster J, Winter J, Krauss S, Ropers HH, et al. MID1, mutated in Opitz syndrome, encodes an ubiquitin ligase that targets phosphatase 2A for degradation. Nat Genet. 2001; 29(3):287–94. https://doi.org/10.1038/ng762 PMID: 11685209.

3. Aranda-Organilles B, Rutschow D, Zeller R, Karagiannis AI, Kohler A, Chen C, et al. Protein phosphatase 2A (PP2A)-specific ubiquitin ligase MID1 is a sequence-dependent regulator of translation efficiency controlling 3-phosphoinositide-dependent protein kinase-1 (PDPK-1). J Biol Chem. 2011; 286(46):39945–57. Epub 2011/09/21. doi: M111.224451 [pii] https://doi.org/10.1074/jbc.M111.224451 PMID: 21930711; PubMed Central PMCID: PMC3220588.

4. Hettich MM, Matthes F, Ryan DP, Griesche N, Schroder S, Dom S, et al. The anti-diabetic drug metformin reduces BACE1 protein level by interfering with the MID1 complex. PLoS One. 2014; 9(7): e102420. https://doi.org/10.1371/journal.pone.0102420 PMID: 25025689; PubMed Central PMCID: PMC4099345.

5. Krauss S, Griesche N, Jastrzebska E, Chen C, Rutschow D, Achmuller C, et al. Translation of HTT mRNA with expanded CAG repeats is regulated by the MID1-PP2A protein complex. Nat Commun. 2013; 4:1511. https://doi.org/10.1038/ncomms2514 PMID: 23443593.

6. Griesche N, Schilling J, Weber S, Rohm M, Pesch V, Matthes F, et al. Regulation of mRNA translation by MID1: a common mechanism of expanded CAG repeat RNAs. Front Cell Neurosci. 2016. https://doi.org/10.3389/fncel.2016.00226 PMID: 27774050.

7. Kohler A, Demir U, Kickstein E, Krauss S, Aigner J, Aranda-Organilles B, et al. A hormone-dependent feedback-loop controls androgen receptor levels by limiting MID1, a novel translation enhancer and promoter of oncogenic signaling. Mol Cancer. 2014; 13(1):146. https://doi.org/10.1186/1476-4598-13-146 PMID: 24913494.

8. Krauss S, Foerster J, Schneider R, Schweiger S. Protein phosphatase 2A and rapamycin regulate the nuclear localization and activity of the transcription factor GLI3. Cancer Res. 2008; 68(12):4658–65. https://doi.org/10.1158/0008-5472.CAN-07-6174 PMID: 18535511.

9. Goodall EF, Heath PR, Bandmann O, Kirby J, Shaw PJ. Neuronal dark matter: the emerging role of microRNAs in neurodegeneration. Front Cell Neurosci. 2013; 7:179. https://doi.org/10.3389/fncel.2013.00178 PMID: 24133413; PubMed Central PMCID: PMC3794211.

10. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136(2):215–33. https://doi.org/10.1016/j.cell.2009.01.002 PMID: 19167326; PubMed Central PMCID: PMC3794896.

11. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120(1):15–20. https://doi.org/10.1016/j.cell.2004.12.035 PMID: 16652477.

12. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell. 2003; 115(7):798–807. PMID: 14697198.

13. Waldvogel HJ, Bullock JY, Synek BJ, Curtis MA, van Roon-Mom WM, Faull RL. The collection and processing of human brain tissue for research. Cell Tissue Bank. 2008; 9(3):169–79. https://doi.org/10.1007/s10561-008-9068-1 PMID: 18357514.
14. Scherzinger E, Lurz R, Turmaine M, Mangiari L, Hollenbach B, Hasenbank R, et al. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell. 1997; 90(3):549–58. PMID: 9267034.

15. Panwar B, Omenn GS, Guan Y. miRnome: a database of human miRNA expression profiles. Bioinformatics. 2017; 33(10):1554–60. https://doi.org/10.1093/bioinformatics/btx019 PMID: 28108447.

16. Arigoni M, Barutello G, Riccardo F, Ercole E, Cantarella D, Orso F, et al. miR-135b coordinates progression of ErbB2-driven mammary carcinomas through suppression of MID1 and MTCH2. Am J Pathol. 2013; 182(6):2058–70. https://doi.org/10.1016/j.ajpath.2013.02.046 PMID: 23623609.

17. Schweiger S, Dorn S, Fuchs M, Kohler A, Matthes F, Muller EC, et al. The E3 Ubiquitin Ligase MID1 Catalyzes Ubiquitination and Cleavage of Fu. J Biol Chem. 2014; 289(46):31805–17. Epub 2014/10/04. doi: M113.541219 [pii] https://doi.org/10.1074/jbc.M113.541219 PMID: 25278022; PubMed Central PMCID: PMC4231658.

18. Wlodarchak N, Xing Y. PP2A as a master regulator of the cell cycle. Crit Rev Biochem Mol Biol. 2016; 51(3):162–84. https://doi.org/10.3109/10409238.2016.1143913 PMID: 26906453; PubMed Central PMCID: PMCPMC4905575.

19. Zhang J, Song Y, Zhang C, Zhi X, Fu H, Ma Y, et al. Circulating MiR-16-5p and MiR-19b-3p as Two Novel Potential Biomarkers to Indicate Progression of Gastric Cancer. Theranostics. 2015; 5(7):733–45. https://doi.org/10.7150/thno.10305 PMID: 25897338; PubMed Central PMCID: PMCPMC4402497.

20. Goswami S, Tarapore RS, Poenitzsch Strong AM, TeStela JJ, Grinblat Y, Setaluri V, et al. MicroRNA-340-mediated degradation of microphthalmia-associated transcription factor (MITF) mRNA is inhibited by coding region determinant-binding protein (CRD-BP). J Biol Chem. 2015; 290(1):384–95. https://doi.org/10.1074/jbc.M114.590158 PMID: 25414259; PubMed Central PMCID: PMC4281741.

21. Xie J, Tan ZH, Tang X, Mo MS, Liu YP, Gan RL, et al. MiR-374b-5p suppresses RECK expression and promotes gastric cancer cell invasion and metastasis. World J Gastroenterol. 2014; 20(46):17439–47. https://doi.org/10.3748/wjg.v20.i46.17439 PMID: 25516656; PubMed Central PMCID: PMCPMC4266603.

22. Li Y, Yao L, Liu F, Hong J, Chen L, Zhang B, et al. Characterization of microRNA expression in serous ovarian carcinoma. Int J Mol Med. 2014; 34(2):491–8. https://doi.org/10.3892/ijmm.2014.1813 PMID: 24939816.

23. Wang Y, Huang JW, Castella M, Huntsman DG, Taniguchi T. p53 is positively regulated by miR-542-3p. Cancer Res. 2014; 74(12):3218–27. https://doi.org/10.1158/0008-5472.CAN-13-1706 PMID: 24762395; PubMed Central PMCID: PMCPMC4058365.

24. Chen BB, Chen XB, Bie LY, Mu Y, Wang HL, Lu HF, et al. Decreased expression of miR-542-3p exerts growth inhibitory functions in esophageal cancer. J Cancer Res Ther. 2015; 11 Suppl 1:C24–8. https://doi.org/10.4103/0973-1482.149373 PMID: 26323919.

25. Ye C, Yue G, Shen Z, Wang B, Yang Y, Li T, et al. MiR-542-3p suppresses colorectal cancer progression through targeting survivin. Translational Cancer Research. 2016; 5(6):817–26.

26. Wu N, Lu Y, Liang JZ. [Expression and correlation of survivin and hsa-miR-542-3p in patients with oral squamous cell carcinoma]. Shanghai Kou Qiang Yi Xue. 2016; 25(6):720–4. PMID: 28275798.

27. Chu EC, Tamawski AS. PTEN regulatory functions in tumor suppression and cell biology. Med Sci Monit. 2004; 10(10):RA235–41. PMID: 15448614.

28. Jeselsohn R, De Angelis C, Brown M, Schiff R. The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer. Curr Oncol Rep. 2017; 19(5):35. https://doi.org/10.1007/s11912-017-0591-8 PMID: 28374222.

29. Zhang J, Wang S, Han F, Li J, Yu L, Zhou P, et al. MicroRNA-542-3p suppresses cellular proliferation of bladder cancer cells through post-transcriptionally regulating survivin. Gene. 2016; 579(2):146–52. https://doi.org/10.1016/j.gene.2015.12.048 PMID: 26723509.

30. Althoff K, Lindner S, Odersky A, Mestdagh P, Beckers A, Karczewski S, et al. miR-542-3p exerts tumor suppressive functions in neuroblastoma by downregulating Survivin. Int J Cancer. 2015; 136(6):1308–20. https://doi.org/10.1002/ijc.29091 PMID: 25046253.

31. Zhang M, Ma F, Xie R, Wu Y, Wu M, Zhang P, et al. Overexpression of Srrc1 contributes to the growth and metastasis of colorectal cancer. Int J Oncol. 2017; 50(5):1555–66. https://doi.org/10.3892/ijo.2017.3952 PMID: 28933242; PubMed Central PMCID: PMC5403293.

32. Wang R, Geng N, Zhou Y, Zhang D, Li L, Li J, et al. Aberrant Wnt-1/beta-catenin signaling and WIF-1 deficiency are important events which promote tumor cell invasion and metastasis in salivary gland adenoid cystic carcinoma. Biomed Mater Eng. 2015; 25 Suppl 1:SI45–53. https://doi.org/10.3233/BME-151520 PMID: 26403993.

33. Lee Y, Samaco RC, Gatчет JR, Thaller C, Orr HT, Zoghbi HY. miR-19, miR-101 and miR-130 co-regulate ATXN1 levels to potentially modulate SCA1 pathogenesis. Nat Neurosci. 2008; 11(10):1137–9. https://doi.org/10.1038/nn.2193 PMID: 18758469; PubMed Central PMCID: PMC2574629.
34. Wozniak M, Sztiler-Sikorska M, Czyz M. Diminution of miR-340-5p levels is responsible for increased expression of ABCB5 in melanoma cells under oxygen-deprived conditions. Exp Mol Pathol. 2015; 99(3):707–16. https://doi.org/10.1016/j.yexmp.2015.11.014 PMID: 26554847.
35. Pan S, Zheng Y, Zhao R, Yang X. miRNA-374 regulates dexamethasone-induced differentiation of primary cultures of porcine adipocytes. Horm Metab Res. 2013; 45(7):518–25. https://doi.org/10.1055/s-0033-1334896 PMID: 23468252.
36. Yoon S, Choi YC, Lee S, Jeong Y, Yoon J, Baek K. Induction of growth arrest by miR-542-3p that targets survivin. FEBS Lett. 2010; 584(18):4048–52. https://doi.org/10.1016/j.febslet.2010.08.025 PMID: 20728447.
37. Mavragis KJ, Wolfe AL, Orcichio E, Palomerro T, de Keersmaecker K, McJunkin K, et al. Genome-wide RNA-mediated interference screen identifies miR-19 targets in T-cell acute lymphoblastic leukaemia. Nat Cell Biol. 2010; 12(4):372–9. https://doi.org/10.1038/nclb2037 PMID: 20190740; PubMed Central PMCID: PMCPMC2989719.
38. Sun Y, Zhao X, Zhou Y, Hu Y, miR-124, miR-137 and miR-340 regulate colorectal cancer growth via inhibition of the Warburg effect. Oncol Rep. 2012; 28(4):1346–52. https://doi.org/10.3892/or.2012.1958 PMID: 22895557.
39. Oneyama C, Morii E, Okuzaki D, Takahashi Y, Ikeda J, Wakabayashi N, et al. MicroRNA-mediated upregulation of integrin-linked kinase promotes Src-induced tumor progression. Oncogene. 2012; 31(13):1623–35. https://doi.org/10.1038/onc.2011.367 PMID: 21860426.
40. Xu XM, Wang XB, Chen MM, Liu T, Li YX, Jia WH, et al. MicroRNA-19a and -19b regulate osteoblast cell proliferation and invasion by targeting CUL5. Cancer Lett. 2012; 322(2):148–58. https://doi.org/10.1016/j.canlet.2012.02.038 PMID: 22561557.
41. Hashimoto Y, Akiyama Y, Yuasa Y. Multiple-to-multiple relationships between microRNAs and target genes in gastric cancer. PLoS One. 2013; 8(5):e62589. https://doi.org/10.1371/journal.pone.0062589 PMID: 23667495; PubMed Central PMCID: PMCPMC3648557.
42. Cai J, Guan H, Fang L, Yang Y, Zhu X, Yuan J, et al. MicroRNA-374a activates Wnt/beta-catenin signaling to promote breast cancer metastasis. J Clin Invest. 2013; 123(2):566–79. https://doi.org/10.1172/JCI65871 PMID: 23438603; PubMed Central PMCID: PMCPMC3561816.
43. Shen X, Si Y, Yang Z, Wang Q, Yuan J, Zhang X. MicroRNA-542-3p suppresses cell growth of gastric cancer cells via targeting oncogene astrocyte-elevated gene-1. Med Oncol. 2015; 32(1):361. https://doi.org/10.1007/s12032-014-0361-5 PMID: 25432696.
44. Kumar P, Luo Y, Tuducla C, Alexander JM, Mendelson CR. The c-Myc-regulated microRNA-17–92 (miR-17–92) and miR-106a–363 clusters target hCYP19A1 and hGCM1 to inhibit human trophoblast differentiation. Mol Cell Biol. 2013; 33(9):1782–96. https://doi.org/10.1128/MCB.01228-12 PMID: 23438603; PubMed Central PMCID: PMCPMC3642183.
45. Song L, Duan P, Gan Y, Li P, Zhao C, Xu J, et al. MicroRNA-340-5p modulates cisplatin resistance by targeting LPAA and Beta in osteosarcoma. Braz J Med Biol Res. 2017; 50(5):e6359. https://doi.org/10.1590/1414-431X20176359 PMID: 28443990; PubMed Central PMCID: PMCPMC5441287.
46. Xu X, Wang W, Su N, Zhu X, Yao J, Gao W, et al. miR-374a promotes cell proliferation, migration and invasion by targeting SRCIN1 in gastric cancer. FEBS Lett. 2015; 589(3):407–13. https://doi.org/10.1016/j.febslet.2014.12.027 PMID: 25554419.
47. Kureel J, Dixit M, Tyagi AM, Mansoori MN, Srivastava K, Raghuvasahi A, et al. miR-542-3p suppresses osteoblast cell proliferation and differentiation, targets BMP-7 signaling and inhibits bone formation. Cell death & disease. 2014; 5:e1227. https://doi.org/10.1038/cddis.2014.4 PMID: 24503542; PubMed Central PMCID: PMCPMC3944264.
48. Castellano L, Giamas G, Jacob J, Coomes BC, Lucchesi W, Thiruchelvam P, et al. The estrogen receptor-alpha-induced microRNA signature regulates itself and its transcriptional response. Proc Natl Acad Sci U S A. 2009; 106(37):15732–7. https://doi.org/10.1073/pnas.0906947106 PMID: 19706389; PubMed Central PMCID: PMCPMC2747188.
49. Wu ZS, Wu Q, Wang CQ, Wang XN, Huang J, Zhao JJ, et al. miR-340 inhibition of breast cancer cell migration and invasion through targeting of oncoprotein c-Met. Cancer. 2011; 117(3):2842–52. https://doi.org/10.1016/cnrcr.2011.04.026 PMID: 21692045.
50. Wang Y, Xia H, Zhuang Z, Mao L, Chen X, Cai H. Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer. Cell death & disease. 2014; 5:e1227. https://doi.org/10.1038/cddis.2014.186 PMID: 24832599; PubMed Central PMCID: PMCPMC4047906.
51. He T, Qi F, Jia L, Wang S, Song N, Guo L, et al. MicroRNA-542-3p inhibits tumor angiogenesis by targeting angiopoietin-2. J Pathol. 2014; 232(5):499–508. https://doi.org/10.1002/path.4324 PMID: 24403060.
52. Wu W, Dang S, Feng Q, Liang J, Wang Y, Fan N. MicroRNA-542-3p inhibits the growth of hepatocellular carcinoma cells by targeting FZD7/Wnt signaling pathway. Biochem Biophys Res Commun. 2017; 482(1):100–5. https://doi.org/10.1016/j.bbrc.2016.10.136 PMID: 27815069.
53. Wu Q, Yang Z, An Y, Hu H, Yin J, Zhang P, et al. MiR-19a/b modulate the metastasis of gastric cancer cells by targeting the tumour suppressor MXD1. Cell death & disease. 2014; 5:e1144. https://doi.org/10.1038/cddis.2014.110 PMID: 24675462; PubMed Central PMCID: PMCPMC3973221.

54. Rang Z, Yang G, Wang YW, Cui F. miR-542-3p suppresses invasion and metastasis by targeting the proto-oncogene serine/threonine protein kinase, PIM1, in melanoma. Biochem Biophys Res Commun. 2016; 474(2):315–20. https://doi.org/10.1016/j.bbrc.2016.04.093 PMID: 27107696.

55. Buechner J, Tomte E, Haug BH, Henriksen JR, Lokke C, Flaegstad T, et al. Tumour-suppressor micro-RNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma. Br J Cancer. 2011; 105(2):296–303. https://doi.org/10.1038/bjc.2011.220 PMID: 21654684; PubMed Central PMCID: PMCPMC3142803.

56. Zhou X, Wei M, Wang W. MicroRNA-340 suppresses osteosarcoma tumor growth and metastasis by directly targeting ROCK1. Biochem Biophys Res Commun. 2013; 437(4):653–8. https://doi.org/10.1016/j.bbrc.2013.07.033 PMID: 23872151.

57. Cai J, Zhao J, Zhang N, Xu X, Li R, Yi Y, et al. MicroRNA-542-3p Suppresses Tumor Cell Invasion via directly targeting ROCK1. Biochem Biophys Res Commun. 2013; 437(4):653–8. https://doi.org/10.1016/j.bbrc.2013.07.033 PMID: 23872151.

58. Jian Q, An Q, Zhu D, Hui K, Liu Y, Chi S, et al. MicroRNA 340 is involved in UVB-induced dendrite formation through the regulation of RhoA expression in melanocytes. Mol Cell Biol. 2014; 34(18):3407–20. https://doi.org/10.1128/MCB.00106-14 PMID: 24980435; PubMed Central PMCID: PMCPMC4135612.

59. Das S, Bryan K, Buckley PG, Piskareva O, Bray IM, Foley N, et al. Modulation of neuroblastoma disease pathogenesis by an extensive network of epigenetically regulated microRNAs. Oncogene. 2013; 32(24):2927–36. https://doi.org/10.1038/onc.2012.311 PMID: 22797059; PubMed Central PMCID: PMCPMC3477270.

60. Fuziwara CS, Kimura ET. High iodine blocks a Notch/miR-19 loop activated by the BRAF(V600E) oncogene. Mol Cells. 2016; 32(24):2927–36. https://doi.org/10.1007/s10059-016-0624-4 PMID: 27386345; PubMed Central PMCID: PMCPMC4836334.

61. Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A. 2008; 105(35):12885–90. https://doi.org/10.1073/pnas.0806202105 PMID: 18728182; PubMed Central PMCID: PMCPMC2529070.

62. Fuziwara CS, Kimura ET. High iodine blocks a Notch/miR-19 loop activated by the BRAF(V600E) oncoprotein and restores the response to TGFbeta in thyroid follicular cells. Thyroid. 2014; 24(3):453–62. https://doi.org/10.1089/thy.2013.0398 PMID: 23998804; PubMed Central PMCID: PMCPMC3949441.

63. Ashraf A, Zhu B, Ye J, Wan S, Nie Y, Chen Z, et al. MicroRNA-19b-3p Modulates Japanese Encephalitis Virus-Mediated Inflammation via Targeting RNF11. J Virol. 2016; 90(9):4780–95. https://doi.org/10.1128/JVI.00106-15 PMID: 26654684; PubMed Central PMCID: PMCPMC4836334.

64. Ashraf A, Zhu B, Ye J, Wan S, Nie Y, Chen Z, et al. MicroRNA-19b-3p Modulates Japanese Encephalitis Virus-Mediated Inflammation via Targeting RNF11. J Virol. 2016; 90(9):4780–95. https://doi.org/10.1128/JVI.00106-15 PMID: 26654684; PubMed Central PMCID: PMCPMC4836334.

65. Zou M, Wang F, Gao R, Wu J, Ou Y, Chen X, et al. Autophagy inhibition of hsa-miR-19a-3p/19b-3p by downregulating miR-340-5p expression to induce STAT3 overexpression. Cell Biosci. 2017; 7:16. https://doi.org/10.1186/s13578-017-0144-8 PMID: 28413603; PubMed Central PMCID: PMCPMC5389182.

66. Philippe L, Alsaleh G, Suffert G, Meyer A, Georgel P, Sibilia J, et al. TLR2 expression is regulated by miR-340 and miR-374 and miR-542 regulate MID1.
71. Fan Y, Yin S, Hao Y, Yang J, Zhang H, Sun C, et al. miR-19b promotes tumor growth and metastasis via targeting TP53. RNA. 2014; 20(6):765–72. https://doi.org/10.1261/rna.043026.113 PMID: 24742936; PubMed Central PMCID: PMCPMC4024631.

72. Hebert SS, Horre K, Nicolai L, Papadopoulou AS, Mandemakers W, Silahtaroglu AN, et al. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci USA. 2008; 105(17):6415–20. https://doi.org/10.1073/pnas.0710263105 PMID: 18434550; PubMed Central PMCID: PMCPMC2359789.

73. Matthes F, Hettich MM, Schilling J, Flores-Dominguez D, Blank N, Wiglenda T, et al. Inhibition of the MID1 protein complex: a novel approach targeting APP protein synthesis. Cell Death Discovery. in press.

74. Schweiger S, Matthes F, Posey K, Kickstein E, Weber S, Hettich MM, et al. Resveratrol induces dephosphorylation of Tau by interfering with the MID1-PP2A complex. Sci Rep. 2017; 7(1):13753. https://doi.org/10.1038/s41598-017-12974-4 PMID: 29062069; PubMed Central PMCID: PMCPMC5653760.

75. Wu Y, Xu J, Xu J, Jiao D, Zhou C, et al. Lower Serum Levels of miR-29c-3p and miR-19b-3p as Biomarkers for Alzheimer's Disease. Tohoku J Exp Med. 2017; 242(2):129–36. https://doi.org/10.1620/tjem.242.129 PMID: 28626163.